Moderna (MRNA) Tops Q2 EPS by 2c; cuts revenue guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts MRNA Hot Sheet
Join SI Premium – FREE
Moderna (NASDAQ: MRNA) reported Q2 EPS of ($3.33), $0.02 better than the analyst estimate of ($3.35). Revenue for the quarter came in at $241 million versus the consensus estimate of $128.41 million.
GUIDANCE:
Moderna sees FY2024 revenue of $3-3.5 billion, versus the consensus of $3.83 billion.
For earnings history and earnings-related data on Moderna (MRNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pharming Group N.V. (PHAR) Reports Q3 results; offers guidance
- Qiagen posts $548M in Q3 2026 net sales amid pending EQT deal
- Morgan Stanley Downgrades NEXTDC Ltd. (NXT:AU) to Equalweight
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
